IRVINE, CA, and HERSTAL, BELGIUM, July 9, 2015 – MDxHealth SA (Euronext: MDXH) (the “Company”) announces, in accordance with article 14 of the Belgian Act of May 2, 2007 on the disclosure of significant shareholdings in listed companies, that it received shareholder notifications from several shareholders listed below. 

Shareholdings after passively crossing the transparency threshold of 15%, as a result of the successful completion of the private placement of 6,150,000 new shares with a group of institutional, qualified and professional investors in and outside of Belgium, which was announced on June 24, 2015 and completed on June 26, 2015.

• Biovest Comm. VA⁽¹⁾                                                  : 13.99%
• Valiance Asset Management Ltd. ⁽²⁾                                    : 13.33%

Shareholdings after actively crossing the transparency threshold of 3%:

• Petercam Institutional Asset Management SA⁽³⁾        : 2.98%
• Petercam SA⁽⁴⁾                                                                               : 0%

Notes:

1. Biovest Comm. VA (“Biovest”) notified on July 1, 2015 that, as a result of the issuance of new shares on June 26, 2015, its shareholding dropped below the threshold of 15% of the outstanding shares. Biovest still holds 6,156,525 shares which now represent 13.99% of the 43,998,490 shares currently outstanding.
2. Valiance Asset Management Ltd. (“Valiance”) notified on July 3, 2015 that, as a result of the issuance of new shares on June 26, 2015, its shareholding dropped below the threshold of 15% of the outstanding shares. Valiance holds 5,866,834 shares in the Company, which now represent 13.33% of the 43,998,490 shares currently outstanding.
3. Petercam Institutional Asset Management SA (jointly with Petercam SA) notified on June 23, 2015 that, as a result of a transfer of 140,820 shares in the Company on June 4, 2015, its shareholding dropped below the threshold of 3% of the number of shares outstanding at that time. Petercam Institutional Asset Management SA is controlled by Petercam SA.  The 2.98% is calculated based on a total number of 37,848,490 shares outstanding at that time.
4. Petercam SA and Petercam Institutional Asset Management SA jointly notified on June 12, 2015 that, as a result of a transfer on March 23, 2015 by Petercam SA to Petercam Institutional Asset Management SA of the voting rights attached to the Company’s shares which are held by Petercam B Fund SA and Petercam Horizon B SA, Petercam SA’s shareholding dropped below the 3% threshold and Petercam Institutional Asset Management SA’s shareholding crossed the 3% threshold. As a result, Petercam Institutional Asset Management SA then held 1,266,914 shares, i.e. 3.38% of the total number of shares outstanding at that time. The 3.38% is calculated based on a total number of 37,848,490 shares outstanding at that time.

About MDxHealth^®
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.